Updated:
Nexstim Oyj
Nexstim Oyj is a Helsinki-based public asset manager developing navigated brain stimulation systems for therapeutic and surgical use.
Nexstim Oyj
Nexstim Oyj, a Finnish public limited company headquartered in Helsinki, was founded to develop and commercialize navigated transcranial magnetic stimulation (nTMS) systems. The firm's technology is used for preoperative mapping of eloquent cortical areas in brain surgery patients and for treating major depressive disorder. Its core intellectual property includes proprietary navigation software that integrates with TMS devices. The company's strategy involves direct sales and distribution partnerships across Europe, North America, and Asia. Nexstim has received CE marking and FDA clearance for its nTMS system. The firm pursues regulatory approvals and insurance reimbursement coverage to expand market access. Its revenue model combines capital equipment sales with recurring consumable revenues. Nexstim's team includes specialists in neurology, neuroscience, and medical device regulatory affairs. The company maintains its headquarters in Helsinki with regional sales and support offices. A recent operational milestone: In 2023, Nexstim reported its first quarters of positive EBITDA (per the firm's financial reports, 2023), signaling progress toward profitability. A structural differentiator: Nexstim is a publicly traded company, not a traditional family office, transparent in its financial disclosures. Its governance includes a board of directors elected by shareholders. This public-company structure provides liquidity and regulatory oversight distinct from private investment entities.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Finland
City
Helsinki
Corporate office
Helsinki, Finland
Frequently asked questions
Does Nexstim operate as a single family office?
No. Nexstim Oyj is a publicly traded Finnish limited company (public record). It does not manage capital for a single family; its governance and transparency obligations follow from its listing status.
What technology does Nexstim develop?
Nexstim develops navigated transcranial magnetic stimulation (nTMS) systems. Its NBS (Navigated Brain Stimulation) system is used for preoperative mapping in brain tumor or epilepsy surgery. The company also offers therapies for major depressive disorder via its eTMS platform (per company disclosures, public record).
What regulatory approvals does Nexstim hold?
Nexstim has received CE marking for its nTMS systems in Europe and FDA 510(k) clearance for its NBS system in the United States (per public regulatory filings). These approvals allow commercial sales in their respective jurisdictions.
How does Nexstim generate revenue?
Nexstim's revenue comes primarily from capital equipment sales of its nTMS systems and recurring consumable products, such as stimulation coils and software licenses. The company also offers service contracts and maintenance arrangements (per the firm's financial reports, public record).
What are Nexstim's target markets?
Nexstim targets hospital neurology departments, neurosurgery clinics, and psychiatric institutions. Its geographic focus includes Europe, North America, and select markets in Asia and the Middle East (per public record).
Does Nexstim have any partnerships or distribution deals?
Yes, Nexstim has established distribution agreements in multiple countries. For example, the company announced a partnership with Chinese distributor to expand market access in China (per company press releases, 2020s public record).
Is Nexstim profitable?
As of its 2023 financial reports, Nexstim reported its first quarters of positive EBITDA (per the firm's financial reports, 2023). The company continues to invest in R&D and commercial expansion, and full-year net profitability has not been sustained consistently.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: